Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2026

Boan Biotech Submits BLA for Aflibercept Intravitreous Injection in Brazil

Boan Biotech announced today that it has submitted a Biologics License Application (BLA) to the Brazilian Health Regulatory Agency (ANVISA) for the company’s Aflibercept Intravitreous Injection ...

VOLUNTARY ANNOUNCEMENT BLA SUBMISSION FOR AFLIBERCEPT INTRAVITREOUS INJECTION IN BRAZIL

China’s CDE Accepts IND Application for Boan Biotech’s BA1203 (A Masked Anti-PD-1/IL-2 Fusion Protein)

Boan Biotech announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for ...

VOLUNTARY ANNOUNCEMENT CDE ACCEPTANCE OF IND APPLICATION FOR BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2026

Boan Biotech Receives CDE Clearance for Phase Ⅱ Clinical Trial of BA1106 in Combination with BA1104 for NSCLC

Yantai, July 2, 2026 –- Boan Biotech announced today that China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has cleared the company’s ap...

VOLUNTARY ANNOUNCEMENT CDE APPROVAL OF PHASE II CLINICAL TRIAL APPLICATION FOR BA1106 IN COMBINATION WITH BA1104 FOR NSCLC

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 JUNE 2026

VOLUNTARY ANNOUNCEMENT LICENSING OF DULAGLUTIDE INJECTION IN THE U.S.